Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 18 October 2012
The Drug Enforcement Administration (DEA) has placed methylone, a powerful stimulant and psychoactive drug most notorious for its presence in bath salts, into its Schedule I of highly restricted drugs with no accepted medical use within the US.
The drug is chemically similar to other drugs like Ecstasy (MDMA), which has been a Schedule I drug under the Controlled Substances Act (CSA) since 1985.
DEA's actions would act to put into place a more permanent solution, overriding an emergency ban it put into place on 21 October 2011. The initial ban was put into place to address concerns that people-and in particular teenagers-were abusing bath salts for their stimulative and psychoactive effects. In particular, the order, "was based on findings by the Administrator of the DEA that the temporary scheduling of these three synthetic cathinones was necessary to avoid an imminent hazard to the public safety," DEA explained in its Federal Register notice.
The temporary order was set to expire on 21 October 2012. Under the FDA Safety and Innovation Act, two of the three forms of cathiones-the class of products to which methylone belongs-addressed by DEA in its October 2011 emergency order were banned and automatically placed into a Schedule I designation. Due to an oversight, says DEA, methylone was not among those three, requiring the agency to issue its 17 October Federal Register notice classifying the drug as Schedule I.
The US Department of Health and Human Services (DHHS) states that there is currently no accepted use for the drug, and that no medical professionals are currently licensed to administer it. The move would also make it more difficult for any company choosing to study the drug to conduct clinical trials or preclinical research.
Tags: Schedule I, Ecstasy, MDMA, Methylone, Batch Salts, DEA, Latest News
Regulatory Focus newsletters
All the biggest regulatory news and happenings.